DE05011213T1 - Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin - Google Patents
Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin Download PDFInfo
- Publication number
- DE05011213T1 DE05011213T1 DE05011213T DE05011213T DE05011213T1 DE 05011213 T1 DE05011213 T1 DE 05011213T1 DE 05011213 T DE05011213 T DE 05011213T DE 05011213 T DE05011213 T DE 05011213T DE 05011213 T1 DE05011213 T1 DE 05011213T1
- Authority
- DE
- Germany
- Prior art keywords
- dosing interval
- beginning
- buprenorphine
- hours
- release rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 title claims abstract 19
- 229960001736 buprenorphine Drugs 0.000 title claims abstract 19
- 230000000202 analgesic effect Effects 0.000 title 1
- 230000003111 delayed effect Effects 0.000 title 1
- 230000037317 transdermal delivery Effects 0.000 claims abstract 13
- 230000036470 plasma concentration Effects 0.000 claims abstract 6
- 238000007726 management method Methods 0.000 claims abstract 3
- 239000000463 material Substances 0.000 claims abstract 2
- 239000011159 matrix material Substances 0.000 claims abstract 2
- 229920000642 polymer Polymers 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Verwendung
einer Polymermatrixschicht, umfassend Buprenorphin oder ein pharmazeutisch akzeptables
Salz davon, und eine Stützschicht,
die aus einem pharmazeutisch akzeptablen Material gefertigt ist,
und welche für
Buprenorphin undurchlässig
ist, bei der Herstellung eines transdermalen Abgabesystems für Buprenorphin,
welches für
die Behandlung von Schmerzen in einem menschlichen Patienten für ein Dosierintervall
von mindestens vier Tagen wirksam ist, wobei das transdermale Abgabesystem
durch Aufbringen des transdermalen Abgabesystems auf die Haut eines
Patienten eine Freisetzungsrate an Buprenorphin über ungefähr ein 72 Stunden Dosierintervall
bereitstellt, so dass eine maximale Plasmakonzentration von 20 pg/ml
bis 850 pg/ml erreicht wird und die transdermale Abgabeeinheit,
wenn sie auf der Haut des Patienten für ein zusätzliches 24 Stunden Intervall
beibehalten wird, Plasmakonzentrationen an Buprenorphin in den Patienten
oberhalb der minimalen wirksamen Konzentrationen an Buprenorphin
bereitstellt, so dass die Patienten während dieses zusätzlichen
Dosierintervalls weiterhin wirksames Schmerzmanagement erfahren.
Claims (8)
- Verwendung einer Polymermatrixschicht, umfassend Buprenorphin oder ein pharmazeutisch akzeptables Salz davon, und eine Stützschicht, die aus einem pharmazeutisch akzeptablen Material gefertigt ist, und welche für Buprenorphin undurchlässig ist, bei der Herstellung eines transdermalen Abgabesystems für Buprenorphin, welches für die Behandlung von Schmerzen in einem menschlichen Patienten für ein Dosierintervall von mindestens vier Tagen wirksam ist, wobei das transdermale Abgabesystem durch Aufbringen des transdermalen Abgabesystems auf die Haut eines Patienten eine Freisetzungsrate an Buprenorphin über ungefähr ein 72 Stunden Dosierintervall bereitstellt, so dass eine maximale Plasmakonzentration von 20 pg/ml bis 850 pg/ml erreicht wird und die transdermale Abgabeeinheit, wenn sie auf der Haut des Patienten für ein zusätzliches 24 Stunden Intervall beibehalten wird, Plasmakonzentrationen an Buprenorphin in den Patienten oberhalb der minimalen wirksamen Konzentrationen an Buprenorphin bereitstellt, so dass die Patienten während dieses zusätzlichen Dosierintervalls weiterhin wirksames Schmerzmanagement erfahren.
- Verwendung eines transdermalen Abgabesystems für Buprenorphin, das vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls eine mittlere Freisetzungsrate von 3 μg/Std. bis 86 μg/Std. an Buprenorphin bereitstellt und, basierend auf einem transdermalen Abgabesystem mit 10 mg Buprenorphin, von 72 Stunden nach dem Beginn des Dosierintervalls bis mindestens 96 Stunden nach dem Beginn des Dosierintervalls eine mittlere Freisetzungsrate von 0,3 μg/Std. bis 9 μg/Std. bereitstellt, bei der Herstellung eines transdermalen Abgabesystems für Buprenorphin, das für die Behandlung von Schmerzen bei einem menschlichen Patienten für ein Dosierintervall von mindestens vier Tagen wirksam ist, wobei das transdermale Abgabesystem durch Aufbringung des transdermalen Abgabesystems auf die Haut eines Patienten über ein 72 Stunden Dosierintervall eine maximale Plasmakonzentration von 20 pg/ml bis 850 pg/ml bereitstellt, und, wenn es für ein zusätzliches 24 Stundenintervall auf der Haut des Patienten beibehalten wird, Plasmakonzentrationen an Buprenorphin oberhalb den minimalen wirksamen Konzentrationen an Buprenorphin bereitstellt, so dass die Patienten während dieses zusätzlichen Dosierintervalls weiterhin wirksames ein Schmerzmanagement erfahren.
- Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 3 μg/Std. bis 5 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 0,3 μg/Std. bis 0,6 μg/Std. von 72 Stunden nach Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
- Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 6 μg/Std. bis 11 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 0,7 μg/Std. bis 1 μg/Std. bis 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
- Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 13 μg/Std. bis 21 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 1 μg/Std. bis 2 μg/Std. von 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
- Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 26 μg/Std. bis 43 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 3 μg/Std. bis 4 μg/Std. von 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
- Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 39 μg/Std. bis 64 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 4 μg/Std. bis 7 μg/Std. von 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
- Verwendung gemäß Anspruch 1 oder 2, wobei die mittleren relativen Freisetzungsraten, die über das Dosierintervall erreicht werden, wie folgt sind: eine mittlere relative Freisetzungsrate von 51 μg/Std. bis 86 μg/Std. vom Beginn des Dosierintervalls bis 72 Stunden nach dem Beginn des Dosierintervalls, und eine mittlere relative Freisetzungsrate von 5 μg/Std. bis 9 μg/Std. von 72 Stunden nach dem Beginn des Dosierintervalls bis zum Ende des Dosierintervalls.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3891997P | 1997-02-24 | 1997-02-24 | |
US38919P | 1997-02-24 | ||
US939068 | 1997-09-29 | ||
US08/939,068 US5968547A (en) | 1997-02-24 | 1997-09-29 | Method of providing sustained analgesia with buprenorphine |
Publications (1)
Publication Number | Publication Date |
---|---|
DE05011213T1 true DE05011213T1 (de) | 2007-09-06 |
Family
ID=26715643
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69835584T Expired - Lifetime DE69835584T2 (de) | 1997-02-24 | 1998-02-24 | Verzögerte analgesie erreicht mit transdermaler verabreichung von buprenorphin |
DE05011213T Pending DE05011213T1 (de) | 1997-02-24 | 1998-02-24 | Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69835584T Expired - Lifetime DE69835584T2 (de) | 1997-02-24 | 1998-02-24 | Verzögerte analgesie erreicht mit transdermaler verabreichung von buprenorphin |
Country Status (22)
Country | Link |
---|---|
US (15) | US5968547A (de) |
EP (9) | EP1570823B1 (de) |
JP (1) | JP2000511936A (de) |
KR (1) | KR100703101B1 (de) |
CN (2) | CN1252705A (de) |
AT (3) | ATE336212T1 (de) |
AU (2) | AU2004218685B2 (de) |
BR (1) | BR9815439A (de) |
CA (1) | CA2276170C (de) |
CZ (2) | CZ299414B6 (de) |
DE (2) | DE69835584T2 (de) |
DK (4) | DK1570823T3 (de) |
ES (4) | ES2387752T3 (de) |
HK (3) | HK1096847A1 (de) |
HU (3) | HU230374B1 (de) |
IL (4) | IL131561A0 (de) |
NO (11) | NO322515B1 (de) |
NZ (1) | NZ337386A (de) |
PL (1) | PL196086B1 (de) |
PT (4) | PT1570823E (de) |
SI (3) | SI0964677T1 (de) |
WO (1) | WO1998036728A2 (de) |
Families Citing this family (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020114827A1 (en) * | 1995-07-28 | 2002-08-22 | Jie Zhang | Methods and apparatus for improved administration of analgesics |
US20040265353A1 (en) * | 1995-07-28 | 2004-12-30 | Zars, Inc. | Systems and methods for treating panic attacks |
US20040024006A1 (en) * | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
US20030211157A1 (en) * | 1996-05-06 | 2003-11-13 | Simon David Lew | Semi-sol delivery blend for water soluble molecules |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
DE19746191C2 (de) | 1997-10-18 | 2000-05-18 | Lohmann Therapie Syst Lts | Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht |
ES2415876T3 (es) | 1997-12-22 | 2013-07-29 | Euro-Celtique S.A. | Forma de dosificación farmacéutica oral que comprende una combinación de un agonista de opiáceos y un antagonista de opiáceos |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
SE9803240D0 (sv) * | 1998-09-24 | 1998-09-24 | Diabact Ab | A pharmaceutical composition having a rapid action |
CN101703777B (zh) | 2000-02-08 | 2012-11-28 | 欧罗赛铁克股份有限公司 | 抗破坏口服阿片样激动剂 |
DE60135441D1 (de) | 2000-02-08 | 2008-10-02 | Euro Celtique Sa | Zusammensetzungen mit kontrollierter freisetzung, die einen opioid agonist und antagonist enthalten |
US6716449B2 (en) | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
US20010033858A1 (en) * | 2000-02-29 | 2001-10-25 | Jie Zhang | Transdermal drug patch |
KR100452972B1 (ko) * | 2000-05-16 | 2004-10-14 | 주식회사 삼양사 | 경피투여용 하이드로젤 조성물 |
AU2001262683A1 (en) * | 2000-06-02 | 2001-12-17 | Teijin Limited | Buprenorphine-containing patch |
GB0021317D0 (en) * | 2000-08-30 | 2000-10-18 | Queen Mary & Westfield College | Transdermal pharmaceutical delivery composition |
AU2002232755A1 (en) * | 2000-10-23 | 2002-05-06 | Euroceltique S.A. | Felodipine transdermal device and methods |
DE60141596D1 (de) | 2000-10-23 | 2010-04-29 | Euro Celtique Sa | Transdermales system zur verabreichung von loratadin und dessen verwendung |
US7018649B2 (en) * | 2000-10-23 | 2006-03-28 | Euro-Celtique, S.A. | Felodipine transdermal device and methods |
US6682757B1 (en) * | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
US20020106407A1 (en) * | 2000-12-11 | 2002-08-08 | Dennis Coleman | Method and apparatus for treating breakthrough pain |
WO2002083135A2 (en) * | 2001-02-16 | 2002-10-24 | Grünenthal GmbH | Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence |
MXPA03006742A (es) * | 2001-02-16 | 2003-10-24 | Gruenenthal Gmbh | Uso de buprenorfina para la terapia de la incontinencia urinaria. |
IL157662A0 (en) * | 2001-03-02 | 2004-03-28 | Euro Celtique Sa | N-but-3-enyl norbuprenorphine and its use as analgesic |
EP1387673B1 (de) | 2001-05-11 | 2010-12-29 | Endo Pharmaceuticals Inc. | Opioid enthaltende arzneiform gegen missbrauch |
WO2003002100A1 (en) * | 2001-06-26 | 2003-01-09 | Farrell John J | Tamper-proof narcotic delivery system |
PT1416842E (pt) | 2001-07-18 | 2009-03-31 | Euro Celtique Sa | Composições farmacêuticas de oxicodona e naloxona |
US20030044458A1 (en) | 2001-08-06 | 2003-03-06 | Curtis Wright | Oral dosage form comprising a therapeutic agent and an adverse-effect agent |
KR20040029405A (ko) | 2001-08-06 | 2004-04-06 | 유로-셀티크 소시에떼 아노뉨 | 방출성 및 격리된 길항제와 오피오이드 효능제의 제제 |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
WO2003013433A2 (en) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Sequestered antagonist formulations |
WO2003014247A1 (en) * | 2001-08-10 | 2003-02-20 | Cosmed. Co., Ltd. | Pressure-sensitive adhesive for the skin and tapes or sheets for the skin made by using the same |
CA2469200A1 (en) * | 2001-12-17 | 2003-06-26 | Aryx Therapeutics | Analgesic delivery systems and methods of use |
US20040033253A1 (en) * | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
ATE394097T1 (de) * | 2002-03-20 | 2008-05-15 | Euro Celtique Sa | Verfahren zur verabreichung von buprenorphin zur behandlung von depression |
EP3241548A1 (de) | 2002-04-05 | 2017-11-08 | Euro-Celtique S.A. | Matrix für nachhaltige, invariante und unabhängige freisetzung von wirkstoffverbindungen |
US20050106249A1 (en) * | 2002-04-29 | 2005-05-19 | Stephen Hwang | Once-a-day, oral, controlled-release, oxycodone dosage forms |
DK2561860T3 (en) * | 2002-05-31 | 2018-04-30 | Titan Pharmaceuticals Inc | Implantable polymer device for prolonged release of buprenorphine |
EP2298302A1 (de) | 2002-06-10 | 2011-03-23 | Euro-Celtique S.A. | Entsorgungssysteme transdermaler Freisetzungsvorrichtungen zum Schutz vor Missbrauch der darin enthaltenen Wirkstoffe |
US7771707B2 (en) | 2004-06-12 | 2010-08-10 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
WO2004014336A2 (de) * | 2002-08-09 | 2004-02-19 | Grünenthal GmbH | Opiod-rezeptor-antagonisten in transdermalen systemen mit buprenorphin |
EP1530469B1 (de) * | 2002-08-20 | 2009-02-25 | Euro-Celtique S.A. | Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form |
US7815934B2 (en) | 2002-09-20 | 2010-10-19 | Alpharma Pharmaceuticals, Llc | Sequestering subunit and related compositions and methods |
WO2004026256A2 (en) * | 2002-09-20 | 2004-04-01 | Alpharma, Inc. | Sustained-release opioid formulations and methods of use |
ATE444296T1 (de) * | 2002-10-25 | 2009-10-15 | Euro Celtique Sa | Analoga und prodrugs von buprenorphin |
JP5054893B2 (ja) * | 2002-12-13 | 2012-10-24 | ユーロ−セルティーク エス.エイ. | 鎮痛のためのブプレノルフィン経皮投与計画 |
AU2003297074A1 (en) * | 2002-12-13 | 2004-07-09 | Euro-Celtique S.A. | Transdermal buprenorphine to treat pain in sickle cell crisis |
EP1913938A1 (de) | 2002-12-13 | 2008-04-23 | Euro-Celtique S.A. | Transdermales Dosierungsschema für Buprenorphin zur Schmerzstillung |
NZ542548A (en) | 2003-03-31 | 2009-04-30 | Titan Pharmaceuticals Inc | Implantable polymeric device for sustained release of dopamine agonist |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
US7879357B2 (en) * | 2003-04-28 | 2011-02-01 | Bayer Schering Pharma Ag | Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients |
EP2316440A1 (de) | 2003-04-30 | 2011-05-04 | Purdue Pharma L.P. | Transdermale Dosierungsformen, die eine Wirkstoffkomponente und eine Entgegengesetzt wirksame Komponente an der Distalen seite der Wirkstoffschicht sowie eine Verbindung für Flüssigkeiten zwischen der Oberfläche mit Wirkstoff und dem Antagonisten enthalten |
US8790689B2 (en) | 2003-04-30 | 2014-07-29 | Purdue Pharma L.P. | Tamper resistant transdermal dosage form |
WO2004103317A2 (en) * | 2003-05-15 | 2004-12-02 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for treatment of diarrhea |
GEP20125454B (en) | 2003-07-25 | 2012-03-26 | Euro Celtique Sa | Treatment of drug dependence withdrawal |
MXPA06000990A (es) * | 2003-07-25 | 2006-04-11 | Euro Celtique Sa | Tratamiento pre-operatorio del dolor post-operatorio. |
US20080020028A1 (en) * | 2003-08-20 | 2008-01-24 | Euro-Celtique S.A. | Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent |
WO2005081825A2 (en) | 2004-02-23 | 2005-09-09 | Euro-Celtique S.A. | Abuse resistance opioid transdermal delivery device |
US7220842B2 (en) | 2004-04-05 | 2007-05-22 | Dade Behring Inc. | Immunoassays for buprenorphine and norbuprenorphine |
EP1604666A1 (de) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit |
EP1702558A1 (de) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Verfahren und Vorrichtung zur Darmtätigkeitserfassung |
US20060281775A1 (en) | 2005-06-14 | 2006-12-14 | Applied Pharmacy Services, Inc. | Two-component pharmaceutical composition for the treatment of pain |
EP1743638A1 (de) | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | Pharmazeutische Formulierungen von substituierten Pyrazolinderivaten |
US8202535B2 (en) * | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US9289583B2 (en) * | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8252328B2 (en) * | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US9066847B2 (en) | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
BRPI0709965C1 (pt) * | 2006-04-13 | 2011-12-20 | Nupathe Inc | farmacocinética da administração iontoforética de sumatriptano |
HUE032156T2 (en) | 2006-06-19 | 2017-09-28 | Alpharma Pharmaceuticals Llc | Pharmaceutical preparations |
EP1897543A1 (de) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine-Waffel zur Substitutionstherapie |
DE102006054731B4 (de) * | 2006-11-21 | 2013-02-28 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie |
DE102006054732B4 (de) * | 2006-11-21 | 2010-12-30 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren |
JPWO2008120562A1 (ja) * | 2007-04-02 | 2010-07-15 | 東洋紡績株式会社 | 帯状疱疹後神経痛治療用錠剤および帯状疱疹後神経痛の治療方法 |
EP2604257B1 (de) * | 2007-08-07 | 2017-06-28 | Acelrx Pharmaceuticals, Inc. | Orale transmukosale Dosierungsformen mit Sufentanil und Triazolam |
US20090082383A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched buprenorphine |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
EP2262367A4 (de) * | 2008-03-08 | 2011-04-20 | Theraquest Biosciences Inc | Pharmazeutische oralzusammensetzungen von buprenorphin und verfahren für ihre verwendung |
CA2728912C (en) * | 2008-06-23 | 2018-04-10 | Biodelivery Sciences International, Inc. | Multidirectional mucosal delivery devices and methods of use |
US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
MX347106B (es) | 2009-03-10 | 2017-04-12 | Euro-Celtique S A * | Coposiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona. |
US8548623B2 (en) | 2009-03-18 | 2013-10-01 | Acelrx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
US20110037455A1 (en) * | 2009-08-17 | 2011-02-17 | Oren Navot | System for measuring electrical power |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
EP2611445B1 (de) * | 2010-09-03 | 2018-08-15 | Zoetis Belgium S.A. | Hochdosierte buprenorphine zusammensetzungen und verwendung als analgetika |
WO2012048455A1 (zh) * | 2010-10-12 | 2012-04-19 | 武汉大学 | 一种抗病毒透皮吸收贴片及其制备方法 |
ES2528650T3 (es) | 2010-11-17 | 2015-02-11 | Hexal Ag | Sistema terapéutico transdérmico que comprende buprenorfina |
DE102011076653A1 (de) | 2011-05-27 | 2012-11-29 | Acino Ag | Transdermales therapeutisches System enthaltend Buprenorphin und eine alpha-Hydroxysäure |
EP2758134B1 (de) | 2011-09-19 | 2019-05-29 | Carmel - Haifa University Economic Corporation Ltd. | Buprenorphin zur behandlung von akuter suizidalität |
SG10201604754VA (en) | 2011-12-12 | 2016-08-30 | Lohmann Therapie Syst Lts | Transdermal delivery system comprising buprenorphine |
CN110123792A (zh) * | 2011-12-21 | 2019-08-16 | 拜欧帝力威瑞科学有限公司 | 用于慢性疼痛缓解的跨粘膜药物传递装置 |
ES2663412T3 (es) * | 2012-01-31 | 2018-04-12 | Grünenthal GmbH | Parche farmacéutico para la administración transdérmica de (1R,4R)-6'-fluor-N,N-dimetil-4-fenil-4',9'-dihidro-3'H-espiro[ciclohexano-1,1'-pirano[3,4-b]indol]-4-amina |
AR092820A1 (es) | 2012-04-17 | 2015-05-06 | Purdue Pharma Lp | Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit |
CN104736176B (zh) * | 2012-08-24 | 2017-10-13 | 英特格拉斯疗法有限公司 | 用于增强治疗剂透皮递送的化学组合物和方法 |
AU2013205080B2 (en) * | 2012-12-12 | 2016-07-07 | Lts Lohmann Therapie-Systeme Ag | Transdermal Delivery System |
EP2938391B1 (de) * | 2012-12-28 | 2022-07-27 | Teikoku Seiyaku Co., Ltd. | Transdermale buprenorphinszusammensetzungen mit verzögerter freisetzung |
ES2599802T3 (es) | 2013-06-04 | 2017-02-03 | Lts Lohmann Therapie-Systeme Ag | Sistema de administración transdérmica |
EP3024461B1 (de) | 2013-07-23 | 2020-05-13 | Euro-Celtique S.A. | Kombination aus oxycodon und naloxon für die verwendung bei der behandlung von schmerzen bei patienten mit schmerzen und einer krankheit, die zur intestinaldysbiose und/oder erhöhung der gefahr bakterieller translokation führt |
DE102014013448A1 (de) | 2014-09-16 | 2016-03-17 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Transdermales Therapeutisches System umfassend Buprenorphin |
US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
MY187877A (en) | 2014-12-23 | 2021-10-26 | Acelrx Pharmaceuticals Inc | Systems, devices and methods for dispensing oral transmucosal dosage forms |
US9656441B2 (en) | 2015-01-08 | 2017-05-23 | Alfred E. Tiefenbacher ( Gmbh & Co. Kg) | Transdermal patch |
KR20170137738A (ko) | 2015-03-10 | 2017-12-13 | 로드스 테크놀로지즈 | 부프레노르핀의 아세테이트 염 및 부프레노르핀의 제조방법 |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
CN111971032A (zh) * | 2018-03-13 | 2020-11-20 | 罗曼治疗系统股份公司 | 包含有机硅丙烯酸杂化聚合物的透皮治疗系统 |
WO2021163529A2 (en) * | 2020-02-13 | 2021-08-19 | Biodelivery Sciences International, Inc. | Methods of treatment with buprenorphine |
EP4238669A1 (de) | 2022-03-02 | 2023-09-06 | Recutech S.r.o. | Verfahren zur herstellung einer wärme-feuchtigkeitsaustauschplatte eines enthalpie-luft-zu-luft-austauschers, wärme-feuchtigkeitsaustauschplatte und eines enthalpietauscher |
Family Cites Families (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3996934A (en) * | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
US4058599A (en) | 1973-02-24 | 1977-11-15 | Bayer Aktiengesellschaft | Ethyleneimine inactivated organisms |
US4262003A (en) * | 1975-12-08 | 1981-04-14 | Alza Corporation | Method and therapeutic system for administering scopolamine transdermally |
US4060084A (en) * | 1976-09-07 | 1977-11-29 | Alza Corporation | Method and therapeutic system for providing chemotherapy transdermally |
US4119713A (en) | 1977-02-09 | 1978-10-10 | Sam Carosio | Analgesic and anti-inflammatory composition |
US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
DE3330750A1 (de) * | 1983-08-26 | 1985-03-14 | Chemische Werke Hüls AG, 4370 Marl | Verfahren zur erzeugung von acetylen und synthese- oder reduktionsgas aus kohle in einem lichtbogenprozess |
GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4636539A (en) | 1984-01-30 | 1987-01-13 | Loctite (Ireland) Limited | Instant adhesive composition utilizing calixarene accelerators |
US4601893A (en) | 1984-02-08 | 1986-07-22 | Pfizer Inc. | Laminate device for controlled and prolonged release of substances to an ambient environment and method of use |
US4588580B2 (en) * | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
DE3546830C2 (de) | 1984-07-23 | 1995-07-20 | Alza Corp | Transdermales Abgabesystem zur Verabreichung von Fentanyl |
US4626539A (en) | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
US4834978A (en) | 1984-10-01 | 1989-05-30 | Biotek, Inc. | Method of transdermal drug delivery |
GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
US4806341A (en) * | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
US4698062A (en) | 1985-10-30 | 1987-10-06 | Alza Corporation | Medical device for pulsatile transdermal delivery of biologically active agents |
DE3634016A1 (de) * | 1986-04-17 | 1987-10-29 | Lohmann Gmbh & Co Kg | Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung |
US4673679A (en) | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
USRE33093E (en) | 1986-06-16 | 1989-10-17 | Johnson & Johnson Consumer Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
JPS62298530A (ja) | 1986-06-16 | 1987-12-25 | Otsuka Pharmaceut Co Ltd | 坐薬用医薬組成物 |
US4938759A (en) | 1986-09-02 | 1990-07-03 | Alza Corporation | Transdermal delivery device having a rate controlling adhesive |
US5344656A (en) * | 1986-09-12 | 1994-09-06 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
US4908027A (en) * | 1986-09-12 | 1990-03-13 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
US4906463A (en) * | 1986-12-22 | 1990-03-06 | Cygnus Research Corporation | Transdermal drug-delivery composition |
US5091405A (en) * | 1987-01-05 | 1992-02-25 | E. I. Du Pont De Nemours And Company | Insecticidal pyrazolines |
US5171576A (en) | 1987-03-09 | 1992-12-15 | Alza Corporation | Prevention of contact allergy by coadministration of a corticosteroid with a sensitizing drug |
US4879297A (en) * | 1987-06-01 | 1989-11-07 | Warner-Lambert Company | Fatty acids and their small chain esters as penetration enhancers in aqueous systems |
DE3812481A1 (de) * | 1987-08-26 | 1989-03-09 | Bayer Ag | Wasserhaertende polymerzubereitung |
US4915954A (en) | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
US4983395A (en) * | 1987-11-12 | 1991-01-08 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US5656286A (en) | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US4994278A (en) * | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Breathable backing |
US5236714A (en) | 1988-11-01 | 1993-08-17 | Alza Corporation | Abusable substance dosage form having reduced abuse potential |
CA2002299A1 (en) * | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Compositions for the transdermal delivery of buprenorphine salts |
US5026556A (en) * | 1988-11-10 | 1991-06-25 | Norwich Eaton Pharmaceuticals, Inc. | Compositions for the transdermal delivery of pharmaceutical actives |
US4945103A (en) * | 1989-01-17 | 1990-07-31 | Michael Cohen | Method of treating pre-menstrual syndrome |
US5336210A (en) * | 1989-02-28 | 1994-08-09 | Teijin Limited | Plaster agent |
US5028435A (en) | 1989-05-22 | 1991-07-02 | Advanced Polymer Systems, Inc. | System and method for transdermal drug delivery |
US4956171A (en) * | 1989-07-21 | 1990-09-11 | Paco Pharmaceutical Services, Inc. | Transdermal drug delivery using a dual permeation enhancer and method of performing the same |
US5091186A (en) * | 1989-08-15 | 1992-02-25 | Cygnus Therapeutic Systems | Biphasic transdermal drug delivery device |
DE3939376C1 (de) * | 1989-11-29 | 1991-05-08 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De | |
US5240711A (en) * | 1989-11-29 | 1993-08-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Transdermal therapeutic system comprising as active component buprenorphine |
US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
EP0432945A1 (de) * | 1989-12-12 | 1991-06-19 | Warner-Lambert Company | Transdermales Abgabesystem zur Behandlung der Kokain- und Heroinsucht |
JP2849937B2 (ja) * | 1990-04-18 | 1999-01-27 | 日東電工株式会社 | 医療用貼付剤 |
KR950005865B1 (ko) * | 1990-04-23 | 1995-06-02 | 데이진 가부시끼가이샤 | 첩부제 |
US5069909A (en) * | 1990-06-20 | 1991-12-03 | Cygnus Therapeutic Systems | Transdermal administration of buprenorphine |
DE4020144A1 (de) * | 1990-06-25 | 1992-01-09 | Lohmann Therapie Syst Lts | Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen |
US5688547A (en) | 1990-08-03 | 1997-11-18 | American Cyanamid Company | Meal replacement composition and method of weight control |
GB9021674D0 (en) * | 1990-10-05 | 1990-11-21 | Ethical Pharma Ltd | Transdermal device |
CN1036343C (zh) | 1990-11-10 | 1997-11-05 | 天津市计划生育研究所 | 新促黄体生成素释放激素拮抗类似物的制备方法 |
PL166095B1 (pl) | 1991-04-03 | 1995-03-31 | Warszawskie Zaklady Farma | Sposób wytwarzania N-cyklopropylometylo-7a -[(S)-1-hydroksy-1,2,2-trimetylopropylo] endo-etano-6,7,8,14-tetrahydronororipaviny |
US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
AU657973B2 (en) | 1991-05-07 | 1995-03-30 | Dynagen, Inc. | A controlled, sustained release delivery system for smoking cessation |
US5149538A (en) * | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
US5225440A (en) * | 1991-09-13 | 1993-07-06 | The United States Of America As Represented By The Department Of Health And Human Services | Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase |
US5238933A (en) * | 1991-10-28 | 1993-08-24 | Sri International | Skin permeation enhancer compositions |
US5229130A (en) | 1991-12-20 | 1993-07-20 | Cygnus Therapeutics Systems | Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems |
US5478577A (en) | 1993-11-23 | 1995-12-26 | Euroceltique, S.A. | Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level |
US5958459A (en) | 1991-12-24 | 1999-09-28 | Purdue Pharma L.P. | Opioid formulations having extended controlled released |
US5272149A (en) | 1992-05-05 | 1993-12-21 | Stalling Reginald W | Symptom controlled receptor substitution for addiction withdrawl |
WO1993023019A1 (en) | 1992-05-11 | 1993-11-25 | Sri International | Transdermal drug delivery systems and related compositions and methods of use |
DE69326848T2 (de) | 1992-05-13 | 2000-01-27 | Alza Corp | Oxybutynin zur transdermalen Verabreichung |
ES2137993T3 (es) | 1992-06-11 | 2000-01-01 | Theratech Inc | La utilizacion de glicerina para moderar el aporte transdermico de medicamentos. |
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
DE4237453C1 (de) | 1992-11-06 | 1993-08-19 | Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De | |
DE4301783C1 (de) * | 1993-01-23 | 1994-02-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil |
US5512593A (en) | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
ES2115231T3 (es) | 1993-04-20 | 1998-06-16 | Hexal Ag | Emplasto con sustancias activas. |
US5613958A (en) * | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
AU7396294A (en) | 1993-06-25 | 1995-01-24 | Alza Corporation | Incorporating poly-n-vinyl amide in a transdermal system |
AU7566994A (en) | 1993-08-16 | 1995-03-14 | Cygnus Therapeutic Systems | Contact adhesive extends wear time on skin |
US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
AU1575195A (en) | 1994-01-20 | 1995-08-08 | Akzo Nobel N.V. | New composition of glycoprotein isoforms having follicle stimulating activity |
JPH07206710A (ja) * | 1994-01-21 | 1995-08-08 | Nitto Denko Corp | 経皮投薬用テープ製剤 |
PE44995A1 (es) | 1994-01-27 | 1995-12-18 | Schering Corp | Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias |
JP2819236B2 (ja) * | 1994-05-06 | 1998-10-30 | 日東電工株式会社 | 経皮吸収製剤 |
US5635203A (en) | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
US20020006438A1 (en) | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US5468457A (en) | 1994-12-22 | 1995-11-21 | Osram Sylvania Inc. | Method of making tungsten-copper composite oxides |
DE4446600A1 (de) | 1994-12-24 | 1996-06-27 | Lohmann Therapie Syst Lts | Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen |
US6024974A (en) * | 1995-01-06 | 2000-02-15 | Noven Pharmaceuticals, Inc. | Composition and methods for transdermal delivery of acid labile drugs |
US5601839A (en) | 1995-04-26 | 1997-02-11 | Theratech, Inc. | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
US5785991A (en) * | 1995-06-07 | 1998-07-28 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
AU6657396A (en) | 1995-07-28 | 1997-02-26 | Novartis Ag | Transdermal system |
CA2182851A1 (en) * | 1995-08-15 | 1997-02-16 | August Masaru Watanabe | Method for treating substance abuse withdrawal |
FR2739731B1 (fr) | 1995-10-09 | 1998-01-02 | Axon Cable Sa | Procede de raccordement de micro-cables coaxiaux aux pistes d'un circuit imprime |
DE19642043A1 (de) * | 1995-10-23 | 1997-04-24 | Hexal Ag | Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht |
US5792740A (en) | 1996-03-08 | 1998-08-11 | Firmenich Sa | Fragrant macrocyclic lactones |
IL126251A (en) | 1996-03-25 | 2003-06-24 | Lohmann Therapie Syst Lts | Layered system for application of an active substance-releasing layer of small thickness and processes for the production thereof |
US6004969A (en) | 1996-04-15 | 1999-12-21 | National Science Council | Transdermal delivery of buprenorphine preparations |
US6271240B1 (en) | 1996-05-06 | 2001-08-07 | David Lew Simon | Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals |
SE9602442D0 (sv) | 1996-06-20 | 1996-06-20 | Astra Ab | Administration of pharmaceuticals |
JPH1036265A (ja) * | 1996-07-19 | 1998-02-10 | Nitto Denko Corp | ブプレノルフィン経皮吸収製剤 |
US5837289A (en) * | 1996-07-23 | 1998-11-17 | Grasela; John C. | Transdermal delivery of medications using a combination of penetration enhancers |
EP0821957A3 (de) | 1996-08-01 | 1998-04-22 | Eli Lilly And Company | Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von Drogenmissbrauch |
US20010006677A1 (en) | 1996-10-29 | 2001-07-05 | Mcginity James W. | Effervescence polymeric film drug delivery system |
AT405158B (de) * | 1996-12-04 | 1999-06-25 | Steyr Daimler Puch Ag | Verfahren zur selbsttätigen steuerung der sperrkupplungen eines allradgetriebenen fahrzeuges und fahrzeug mit knicklenkung und sperrbaren differentialen |
US6787149B1 (en) | 1996-12-12 | 2004-09-07 | El Khoury And Stein Ltd. | Topical application of opioid analgesic drugs such as morphine |
DE19652188C2 (de) * | 1996-12-16 | 2002-02-14 | Lohmann Therapie Syst Lts | Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung |
CA2280033A1 (en) | 1997-02-07 | 1998-08-13 | Susan Rako | Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency |
US5968547A (en) | 1997-02-24 | 1999-10-19 | Euro-Celtique, S.A. | Method of providing sustained analgesia with buprenorphine |
WO1998048811A1 (en) | 1997-04-30 | 1998-11-05 | Human Pheromone Sciences, Inc. | Method of fixing fragrances in fragrance composition and other compositions |
US5919473A (en) * | 1997-05-12 | 1999-07-06 | Elkhoury; George F. | Methods and devices for delivering opioid analgesics to wounds via a subdermal implant |
US5900420A (en) | 1997-06-19 | 1999-05-04 | Cole; William L. | Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine |
GB2328443B (en) | 1997-08-21 | 2001-09-05 | Reckitt & Colmann Prod Ltd | In situ formation of pharmaceutically acceptable polymeric material |
US5942530A (en) | 1997-08-28 | 1999-08-24 | Eli Lilly And Company | Method for treating pain |
DE19738855C2 (de) | 1997-09-05 | 2001-01-04 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit haftklebender Reservoirschicht und unidirektional elastischer Rückschicht |
RS49982B (sr) * | 1997-09-17 | 2008-09-29 | Euro-Celtique S.A., | Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2 |
US7011843B2 (en) | 1997-10-01 | 2006-03-14 | Lts Lohmann-Therapie Systeme Ag | Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system |
DE19746191C2 (de) * | 1997-10-18 | 2000-05-18 | Lohmann Therapie Syst Lts | Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht |
US6210705B1 (en) | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
TR200001828T2 (tr) | 1997-12-22 | 2000-11-21 | Euro-Celtique, S.A. | Opioid dozaj şekillerinin kötüye kullanımını önlemeye yönelik bir yöntem. |
US6242456B1 (en) | 1998-03-09 | 2001-06-05 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors |
DE69913111T2 (de) | 1998-03-23 | 2004-06-03 | Elan Corp. Plc | Vorrichtung zur arzneimittelverarbreichung |
JP2002512950A (ja) | 1998-04-29 | 2002-05-08 | バイロテックス コーポレイション | 粘膜表面への、薬剤化合物の送達に適する薬剤キャリアデバイス |
DE19840758A1 (de) | 1998-09-07 | 2000-03-09 | Liedtke Pharmed Gmbh | Systemische Therapie von Schmerz- und depressiver Befindlichkeit |
KR100383252B1 (ko) * | 1998-12-17 | 2003-07-16 | 주식회사 삼양사 | 부프레놀핀을함유하는경피투여조성물및이를포함하는패취 |
US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
IT1305303B1 (it) | 1999-03-10 | 2001-05-04 | Farmigea Spa | Uso dell'olio essenziale di niaouli come promotore per la permeazionetransdermica. |
US6210699B1 (en) | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
US6554851B1 (en) | 1999-05-07 | 2003-04-29 | Scimed Life Systems, Inc. | Methods of sealing an injection site |
US6436977B1 (en) * | 1999-09-29 | 2002-08-20 | Pfizer Inc. | Dosing regimens for lasofoxifene |
US6716449B2 (en) * | 2000-02-08 | 2004-04-06 | Euro-Celtique S.A. | Controlled-release compositions containing opioid agonist and antagonist |
JP4659943B2 (ja) * | 2000-02-25 | 2011-03-30 | 帝三製薬株式会社 | 塩酸ブプレノルフィン含有貼付剤 |
US7067116B1 (en) | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
ATE460939T1 (de) | 2000-08-30 | 2010-04-15 | Unimed Pharmaceuticals Llc | Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern |
US6682757B1 (en) * | 2000-11-16 | 2004-01-27 | Euro-Celtique, S.A. | Titratable dosage transdermal delivery system |
IL157662A0 (en) | 2001-03-02 | 2004-03-28 | Euro Celtique Sa | N-but-3-enyl norbuprenorphine and its use as analgesic |
AU2002305066B8 (en) | 2001-03-23 | 2008-04-17 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting GM1-ganglioside |
ES2487514T3 (es) * | 2001-04-23 | 2014-08-21 | Euro-Celtique S.A. | Sistema de eliminación para forma de dosificación transdérmica |
WO2002087482A1 (en) | 2001-05-01 | 2002-11-07 | Euro-Celtique | Abuse resistant opioid containing transdermal systems |
EP1390866B1 (de) | 2001-05-22 | 2010-01-20 | Euro-Celtique S.A. | Behälter und verfahren zum abgeben transdermaler dosierungsformen |
JP2004527663A (ja) | 2001-06-04 | 2004-09-09 | キネティック リミテッド | パターニング方法 |
WO2003009805A2 (en) | 2001-07-23 | 2003-02-06 | Brigham And Women's Hospital, Inc. | Analgesic methods using endothelin receptor ligands |
WO2003037313A2 (en) | 2001-10-31 | 2003-05-08 | Recovery Pharmaceuticals, Inc. | Methods for the treatment of addiction |
ATE394097T1 (de) * | 2002-03-20 | 2008-05-15 | Euro Celtique Sa | Verfahren zur verabreichung von buprenorphin zur behandlung von depression |
ATE382050T1 (de) * | 2002-11-25 | 2008-01-15 | Chi Mei Foundation Medical Ct | Buprenorphinesterderivate, verfahren zu ihrer herstellung, und langwirksame analgetische arzneimittel |
AU2003297074A1 (en) * | 2002-12-13 | 2004-07-09 | Euro-Celtique S.A. | Transdermal buprenorphine to treat pain in sickle cell crisis |
JP5054893B2 (ja) | 2002-12-13 | 2012-10-24 | ユーロ−セルティーク エス.エイ. | 鎮痛のためのブプレノルフィン経皮投与計画 |
WO2004103317A2 (en) | 2003-05-15 | 2004-12-02 | Euro-Celtique S.A. | Transdermal buprenorphine dosage regimen for treatment of diarrhea |
GEP20125454B (en) | 2003-07-25 | 2012-03-26 | Euro Celtique Sa | Treatment of drug dependence withdrawal |
MXPA06000990A (es) | 2003-07-25 | 2006-04-11 | Euro Celtique Sa | Tratamiento pre-operatorio del dolor post-operatorio. |
US20070059254A1 (en) | 2003-08-21 | 2007-03-15 | Transoral Pharmaceuticals, Inc. | Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof |
WO2006119286A1 (en) | 2005-05-03 | 2006-11-09 | Innozen, Inc. | Edible film for transmucosal delivery of nutritional supplements |
CA2629046C (en) | 2005-12-13 | 2014-04-08 | Biodelivery Sciences International, Inc. | Abuse resistant transmucosal drug delivery device |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
CA2787343C (en) | 2006-06-26 | 2016-08-02 | Amgen Inc. | Compositions comprising modified lcat and uses thereof |
KR101230804B1 (ko) | 2006-07-21 | 2013-02-08 | 바이오딜리버리 사이언시스 인터내셔널 인코포레이티드 | 향상된 흡수를 갖는 경점막 전달 장치 |
EP1897543A1 (de) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine-Waffel zur Substitutionstherapie |
DK2248519T3 (en) | 2006-10-02 | 2018-01-02 | Applied Pharma Res | Non-mucoadhesive film dosage forms |
WO2008042508A1 (en) | 2006-10-03 | 2008-04-10 | University Of Southern California | Grp78 as a predictor of responsiveness to therapeutic agents |
GB2447016A (en) | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Buprenorphine/naloxone compositions |
US20080226702A1 (en) | 2007-03-16 | 2008-09-18 | Endo Pharmaceuticals, Inc. | Transdermal Delivery Form Disposal Systems and Methods |
CA2728912C (en) | 2008-06-23 | 2018-04-10 | Biodelivery Sciences International, Inc. | Multidirectional mucosal delivery devices and methods of use |
ES2528650T3 (es) | 2010-11-17 | 2015-02-11 | Hexal Ag | Sistema terapéutico transdérmico que comprende buprenorfina |
-
1997
- 1997-09-29 US US08/939,068 patent/US5968547A/en not_active Ceased
-
1998
- 1998-02-24 DK DK05011213.5T patent/DK1570823T3/da active
- 1998-02-24 ES ES10185240T patent/ES2387752T3/es not_active Expired - Lifetime
- 1998-02-24 EP EP05011213A patent/EP1570823B1/de not_active Revoked
- 1998-02-24 HU HU0002342A patent/HU230374B1/hu unknown
- 1998-02-24 EP EP10185241A patent/EP2301494A1/de not_active Withdrawn
- 1998-02-24 CA CA002276170A patent/CA2276170C/en not_active Expired - Lifetime
- 1998-02-24 DK DK98906678T patent/DK0964677T3/da active
- 1998-02-24 EP EP10185233A patent/EP2305192A1/de not_active Withdrawn
- 1998-02-24 ES ES98906678T patent/ES2271988T3/es not_active Expired - Lifetime
- 1998-02-24 ES ES05011213T patent/ES2380023T3/es not_active Expired - Lifetime
- 1998-02-24 PT PT05011213T patent/PT1570823E/pt unknown
- 1998-02-24 EP EP10185237A patent/EP2305193A1/de not_active Withdrawn
- 1998-02-24 EP EP10185240A patent/EP2305194B1/de not_active Revoked
- 1998-02-24 AT AT98906678T patent/ATE336212T1/de active
- 1998-02-24 CZ CZ0300999A patent/CZ299414B6/cs not_active IP Right Cessation
- 1998-02-24 EP EP10185235A patent/EP2301493A1/de not_active Withdrawn
- 1998-02-24 SI SI9830859T patent/SI0964677T1/sl unknown
- 1998-02-24 HU HU1200599A patent/HU230608B1/hu unknown
- 1998-02-24 EP EP06118876.9A patent/EP1731152B1/de not_active Revoked
- 1998-02-24 PT PT98906678T patent/PT964677E/pt unknown
- 1998-02-24 AT AT10185240T patent/ATE556682T1/de active
- 1998-02-24 WO PCT/US1998/003584 patent/WO1998036728A2/en active Application Filing
- 1998-02-24 CN CN98804261A patent/CN1252705A/zh active Pending
- 1998-02-24 PT PT10185240T patent/PT2305194E/pt unknown
- 1998-02-24 DK DK06118876.9T patent/DK1731152T3/da active
- 1998-02-24 ES ES06118876T patent/ES2423925T3/es not_active Expired - Lifetime
- 1998-02-24 HU HUP1500370 patent/HUP1500370D0/hu unknown
- 1998-02-24 SI SI9830933T patent/SI1570823T1/sl unknown
- 1998-02-24 SI SI9830937T patent/SI2305194T1/sl unknown
- 1998-02-24 PT PT61188769T patent/PT1731152E/pt unknown
- 1998-02-24 NZ NZ337386A patent/NZ337386A/en not_active IP Right Cessation
- 1998-02-24 BR BR9815439-7A patent/BR9815439A/pt not_active Application Discontinuation
- 1998-02-24 EP EP98906678A patent/EP0964677B1/de not_active Revoked
- 1998-02-24 AT AT05011213T patent/ATE538765T1/de active
- 1998-02-24 DK DK10185240.8T patent/DK2305194T3/da active
- 1998-02-24 CZ CZ2015-477A patent/CZ2015477A3/cs unknown
- 1998-02-24 JP JP10536980A patent/JP2000511936A/ja active Pending
- 1998-02-24 KR KR1019997007713A patent/KR100703101B1/ko active IP Right Grant
- 1998-02-24 EP EP10185230A patent/EP2305191A1/de not_active Withdrawn
- 1998-02-24 CN CN2005101286952A patent/CN1827107B/zh not_active Expired - Lifetime
- 1998-02-24 PL PL335306A patent/PL196086B1/pl unknown
- 1998-02-24 IL IL13156198A patent/IL131561A0/xx unknown
- 1998-02-24 DE DE69835584T patent/DE69835584T2/de not_active Expired - Lifetime
- 1998-02-24 DE DE05011213T patent/DE05011213T1/de active Pending
-
1999
- 1999-05-14 US US09/311,997 patent/US6231886B1/en not_active Ceased
- 1999-08-24 IL IL131561A patent/IL131561A/en not_active IP Right Cessation
- 1999-08-24 NO NO994087A patent/NO322515B1/no not_active IP Right Cessation
-
2001
- 2001-01-08 US US09/756,419 patent/US6344212B2/en not_active Ceased
- 2001-12-27 US US10/033,056 patent/US20030091631A1/en not_active Abandoned
-
2003
- 2003-03-28 US US10/402,288 patent/US20030198675A1/en not_active Abandoned
-
2004
- 2004-10-08 AU AU2004218685A patent/AU2004218685B2/en not_active Expired
-
2006
- 2006-05-26 US US11/442,512 patent/US20060216340A1/en not_active Abandoned
- 2006-09-28 NO NO20064395A patent/NO329734B1/no not_active IP Right Cessation
-
2007
- 2007-02-12 HK HK07101623.6A patent/HK1096847A1/xx not_active IP Right Cessation
- 2007-05-01 US US11/799,611 patent/USRE41489E1/en not_active Expired - Lifetime
- 2007-05-01 US US11/799,610 patent/USRE41571E1/en not_active Expired - Lifetime
- 2007-05-01 US US11/799,608 patent/USRE41408E1/en not_active Expired - Lifetime
- 2007-06-12 HK HK07106323.8A patent/HK1103621A1/xx not_active IP Right Cessation
- 2007-08-22 NO NO20074292A patent/NO329838B1/no not_active IP Right Cessation
-
2008
- 2008-12-19 AU AU2008261134A patent/AU2008261134B2/en not_active Expired
-
2009
- 2009-10-11 IL IL201437A patent/IL201437A/en not_active IP Right Cessation
-
2010
- 2010-07-18 IL IL207067A patent/IL207067A/en not_active IP Right Cessation
- 2010-08-23 NO NO20101190A patent/NO332248B1/no unknown
- 2010-09-22 US US12/888,298 patent/US20110288112A1/en not_active Abandoned
-
2011
- 2011-07-19 HK HK11107538.1A patent/HK1153377A1/xx not_active IP Right Cessation
- 2011-10-24 NO NO20111441A patent/NO333374B1/no not_active IP Right Cessation
-
2012
- 2012-05-14 NO NO20120563A patent/NO333139B1/no unknown
- 2012-10-29 US US13/663,033 patent/US20130197020A1/en not_active Abandoned
-
2013
- 2013-02-26 NO NO20130298A patent/NO334290B1/no unknown
- 2013-11-14 US US14/080,168 patent/US20140073663A1/en not_active Abandoned
- 2013-11-18 NO NO20131533A patent/NO337094B1/no active Protection Beyond IP Right Term
-
2014
- 2014-07-15 US US14/331,966 patent/US20150157625A1/en not_active Abandoned
-
2015
- 2015-09-08 US US14/847,211 patent/US20160220559A1/en not_active Abandoned
- 2015-10-26 NO NO20151450A patent/NO340067B1/no active Protection Beyond IP Right Term
-
2016
- 2016-07-18 NO NO2016013C patent/NO2016013I1/no unknown
- 2016-11-15 US US15/351,879 patent/US9642850B2/en not_active Expired - Fee Related
-
2017
- 2017-04-04 NO NO2017011C patent/NO2017011I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE05011213T1 (de) | Analgetisch wirksame Zusammensetzung mit verzögerter Wirkstoffabgabe von Buprenorphin | |
EP2094249B1 (de) | Transdermales therapeutisches system zur verabreichung des wirkstoffs buprenorphin | |
DE60100595T2 (de) | Verbessertes transdermales therapeutisches System zur Behandlung von Morbus Parkinson | |
DE60100994T2 (de) | Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson | |
CA2528160A1 (en) | Use of 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine for neuronal regeneration and functional recovery | |
CA2314326A1 (en) | Transdermal therapeutic device and method with capsaicin and capsaicin analogs | |
WO1998008546A3 (en) | Therapeutic combinations of rar antagonists and rxr agonists and use thereof | |
DD296844A5 (de) | Verfahren zur herstellung eines pflasters als transdermales therapeutisches system zur verabreichung von wirkstoffen an die haut mit einer abgestuften wirkstoffabgabe sowie verwendung | |
WO2001013902A2 (de) | Wirkstoffkombination enthaltend clonidin und pramipexol | |
Caraceni et al. | Study of the excitability cycle of the blink reflex in Huntington’s chorea | |
DE19654468C1 (de) | Extrem flexibles, dermal oder transdermal wirkendes Pflaster und Verfahren zu seiner Herstellung | |
EP1978995A1 (de) | Verfahren zur behandlung und/oder prophylaxe von multipler sklerose, sowie verwendung von erythropoietin zur herstellung eines arzneimittels zur intermittierenden behandlung und/oder intermittierenden prophylaxe von multipler sklerose | |
DE19746191C2 (de) | Verfahren zur Anwendung eines Wirkstoff enthaltenden Pflasters zur Bekämpfung oder Linderung einer Sucht | |
DE2006696A1 (de) | Pflaster oder Haftverband | |
DE19850517B4 (de) | Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall | |
Vazquez et al. | The effects of sensory stimulation on REM sleep duration | |
WO2006030030A2 (de) | System zur sequentiellen, transdermalen verabreichung von systemisch wirksamen substanzen | |
Maier | Calcitonin | |
DE60024408T2 (de) | Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen | |
DE10293600B4 (de) | Rezeptoradaptierter Nikotinentzug durch anticholinerge und noradrenerge Blockade | |
DE10133576A1 (de) | Verwendung von physiologisch aktiven Oligopeptiden zur Stabilisierung des Immunsystems | |
DE2057174A1 (de) | Pharmazeutisches Produkt,insbesondere injizierbares Lokalanaesthetikum | |
Rezaković et al. | Acute and chronic efficacy of 10 mg of nitroglycerin patch in stable angina pectoris | |
DE4303530C2 (de) | Pharmazeutische Verwendung eines Enkephalins | |
Rudolf | Klinische Effekte des therapeutischen Schlafentzugs |